

ORIGINAL RESEARCH

published: 08 June 2015 doi: 10.3389/fmicb.2015.00574

Characterization and evaluation of antimicrobial and cytotoxic effects of *Streptomyces* sp. HUST012 isolated from medicinal plant *Dracaena* cochinchinensis Lour.

OPEN ACCESS

Edited by:

Sheng Qin, Jiangsu Normal University, China

Reviewed by:

Mohammad Ali Amoozegar, University of Tehran, Iran Kannika Duangmal, Kasetsart University, Thailand Arinthip Thamchaipenet, Kasetsart University, Thailand

*Correspondence:

Wen-Jun Li, Key Laboratory of Microbial Diversity in Southwest China, Ministry of Education, Yunnan Institute of Microbiology, Yunnan University, Kunming 650091, China wjli@ynu.edu.cn; liact@hotmail.com

Specialty section:

This article was submitted to Extreme Microbiology, a section of the journal Frontiers in Microbiology

Received: 31 January 2015 Accepted: 25 May 2015 Published: 08 June 2015

Citation:

Khieu T-N, Liu M-J, Nimaichand S, Quach N-T, Chu-Ky S, Phi Q-T, Vu T-T, Nguyen T-D, Xiong Z, Prabhu DM and Li W-J (2015) Characterization and evaluation of antimicrobial and cytotoxic effects of Streptomyces sp. HUST012 isolated from medicinal plant Dracaena cochinchinensis Lour. Front. Microbiol. 6:574. doi: 10.3389/fmicb.2015.00574 Thi-Nhan Khieu ^{1,2}, Min-Jiao Liu ^{1,3}, Salam Nimaichand ⁴, Ngoc-Tung Quach ⁵, Son Chu-Ky², Quyet-Tien Phi ⁵, Thu-Trang Vu², Tien-Dat Nguyen ⁶, Zhi Xiong ³, Deene M. Prabhu ¹ and Wen-Jun Li ^{1,4*}

¹ Key Laboratory of Microbial Diversity in Southwest China, Ministry of Education, Yunnan Institute of Microbiology, Yunnan University, Kunming, China, ² Department of Food Technology, School of Biotechnology and Food Technology, Hanoi University of Science and Technology, Hanoi, Vietnam, ³ Key Laboratory for Forest Resources Conservation and Use in the Southwest Mountains of China, Ministry of Education, Southwest Forestry University, Kunming, China, ⁴ State Key Laboratory of Biocontrol, Key Laboratory of Biodiversity Dynamics and Conservation of Guangdong Higher Education Institutes, College of Ecology and Evolution, Sun Yat-Sen University, Guangzhou, China, ⁵ Laboratory of Fermentation Technology, Institute of Biotechnology, Vietnam Academy of Science and Technology, Hanoi, Vietnam, ⁶ Department of Bioactive Products, Institute of Marine Biochemistry, Vietnam Academy of Science and Technology, Hanoi, Vietnam

A highly potent secondary metabolite producing endophytic strain, *Streptomyces* sp. HUST012 was isolated from the stems of the medicinal plant *Dracaena cochinchinensis* Lour. Strain HUST012 showed antimicrobial and antitumor activities which were significantly much higher than those of dragon's blood extracted from *D. cochinchinensis* Lour. On further analysis, the strain was found to produce two metabolites, SPE-B11.8 (elucidated to be a novel metabolite (Z)-tridec-7-ene-1,2,13-tricarboxylic acid) and SPE-B5.4 (elucidated as Actinomycin-D). The Minimum Inhibitory Concentration values of SPE-B11.8 against a set of test bacterial organisms (Methicillin-resistant *Staphylococcus epidermis* ATCC 35984, Methicillin-resistant *Staphylococcus aureus* ATCC 25923, *Escherichia coli* ATCC 25922, and *Klebsiella pneumoniae* ATCC 13883) ranged between 15.63 and 62.5 μ g/ml while that for SPE-B5.4 ranged between 0.04 and 2.24 μ g/ml. The compound SPE-B11.8 showed cytotoxic effect at 41.63 and 29.54 μ g/ml IC₅₀-values against Hep G2 and MCF-7, respectively, while the compound SPE-B5.4 exhibited stronger activities against them at 0.23 and 0.18 μ g/ml IC₅₀-values.

Keywords: endophytic, *Streptomyces* sp. HUST012, *Dracaena cochinchinensis* Lour., antimicrobial and cytotoxic activities, (*Z*)-tridec-7-ene-1,2,13-tricarboxylic acid, Actinomycin-D

Introduction

Streptomyces spp. have been shown to possess the ability to synthesize antibacterial, antifungal, insecticidal, antitumor, anti-inflammatory, anti-parasitic, antiviral, anti-infective, antioxidant, and herbicidal compounds (Qin et al., 2011; Kawahara et al., 2012). Nearly 70% of the natural antibiotics used in clinical practices were produced by actinobacteria (Subramani and Aalbersberg, 2012) of

1

which 75–80% have been derived from *Streptomyces* alone (Inbar and Lapidot, 1988; Olano et al., 2004; Rehm et al., 2009; Crnovcic et al., 2013).

The plant Dracaena cochinchinensis Lour, has been used as a traditional medicine since ancient times in the form of Dragon's blood, a deep red resin. Dragon's blood has been shown to illustrate antimicrobial, antiviral, antitumor, cytotoxic, analgesic, antioxidative, anti-inflammatory, haemostatic, antidiuretic, antiulcer and wound healing activities (Gupta et al., 2008). It also finds application as coloring materials and wood varnish (Gupta et al., 2008). However, the slow growth in combination with its low dragon's blood yield results in the destruction of large number of century old plant for harvesting a few milligrams of dragon's blood (Fan et al., 2008). This current study was conducted to explore a sustainable way of utilizing the medicinal plant by studying the endophytic actinomycetes associated with the plant. This paper incorporated the results of the characterization and the evaluation of cytotoxic and antimicrobial effects of an endophytic Streptomyces sp. strain, isolated from the medicinal plant D. cochinchinensis Lour. in comparison with those of dragon's blood extracted from the host plant. The paper also reported the structure elucidation of the bioactive metabolites extracted from the endophytic actinobacteria.

Materials and Methods

Sample Collection and Isolation of Endophytic Actinomycete

Healthy stems of D. cochinchinensis Lour. plant were collected from Cuc Phuong National Park, Ninh Binh province, Vietnam (20° 19′ 8″N, 105° 37′ 20″E; 338 m). The samples were surface sterilized and plated on Sodium propionate medium (Qin et al., 2009). The medium was supplemented with nalidixic acid (25 mg/l), nystatin (50 mg/l), and $K_2Cr_2O_7$ (50 mg/l) to inhibit the growth of Gram-negative bacteria and fungi and polyvinyl pyrolidone (PVP) 2% and tannase 0.005% to improve the growth of colonies. Actinomycetes colonies grown on this culture media were selected and purified by repeated streaking onto International *Streptomyces* Project (ISP) 2 medium. The purified strain HUST012 was preserved as glycerol suspensions (20%, v/v) and as lyophilized spore suspensions in skim milk at -80° C (Zhang et al., 2010).

Characterization of the Endophytic Isolate HUST012

The endophytic isolate HUST012 was characterized on the basis of the physiological and biochemical properties and the analysis of 16S rRNA gene sequence. Morphological and growth patterns were observed on different media (Shirling and Gottlieb, 1966). Morphological characteristics were observed by light microscopy (Olympus BH2) and scanning electron microscopy (JSM-6610LV, JEOL Ltd.) (Anderson and Wellington, 2001). The ability of the isolate to grow at different pH (4.0–10.0, at intervals of 1.0 pH unit using the buffer system as described by Xu et al., 2005) and concentration of NaCl (0, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 10.0, 11.0, 12.0, 15.0%, w/v) was examined on ISP 2 medium.

Growth was tested at 4, 10, 20, 25, 28, 37, 45, and 55°C using ISP2 medium. The hydrolysis of starch, casein and gelatin was carried out according to the methods described by Tindall et al. (2007). Nitrate reduction and H₂S production were determined using conventional procedures (Goodfellow, 1971; Athalye et al., 1985). Utilization of the carbon source was performed as previously described (Shirling and Gottlieb, 1966; Athalye et al., 1985; Mechri et al., 2014) using the basal medium recommended by Pridham and Gottlieb (1948).

The isolation of genomic DNA and PCR amplification for 16S rRNA gene was performed as previously described (Li et al., 2009). The identification of phylogenetic neighbors and calculation of pairwise 16S rRNA gene sequence similarities were achieved using the EzTaxon server (http://www.eztaxon.org/) (Kim et al., 2012) and BLAST analysis (http://blast.ncbi.nlm. nihgov/Blast.cgi). Multiple sequence alignment was done using CLUSTALW (Thompson et al., 1997). The phylogenetic tree was constructed using the aligned sequences by the neighbor-joining method (Saitou and Nei, 1987) using Kimura-2-parameter distances (Kimura, 1983) in the MEGA 6 software (Tamura et al., 2013). To determine the support of each clade, bootstrap analysis was performed with 1000 replications (Felsenstein, 1985).

The GenBank accession number for the partial 16S rRNA gene sequences of strain HUST012 is KP330557.

Evaluation of Antimicrobial Activities

The antibacterial activities was evaluated against Methicillinsusceptible *Staphylococcus aureus* (MSSA) ATCC 29213, Methicillin-resistant *Staphylococcus epidermidis* (MRSE) ATCC 35984, Methicillin-resistant *Staphylococcus aureus* (MRSA) ATCC 25923, *Klebsiella pneumoniae* ATCC 13883, *Aeromonas hydrophila* ATCC 7966, *Escherichia coli* ATCC 25922, *Escherichia coli* ATCC 11105, and *Enterococcus faecalis* ATCC 29212 using the agar well diffusion method (Holder and Boyce, 1994). The Minimum Inhibitory Concentration (MIC) was determined as previously described (Andrews, 2001).

The animal fungal pathogens Fusarium graminearum, Aspergillus carbonarius, and Aspergillus westerdijkiae which were known to produce strong toxic deoxynivalenol (DON) and ochratoxin A (Khamna et al., 2009; Huffman et al., 2010) were kindly provided by UMR Qualisud, CIRAD, France. These strains were maintained on Potato Dextrose Agar (PDA) medium (Liu et al., 2002). For the determination of antifungal activity, culture broth of HUST012 (100 ml) was centrifuged at 7000 g for 10 min. The supernatant was collected and added to the PDA medium (pH 5.5) at a concentration of 15% (v/v). Sterilized water was used as control. The resulting PDA plates were inoculated with the different fungal strains and incubated for 5 days at 28°C. The fungal radial growth was measured. Each experiment was carried out in triplicates.

Determination of Cytotoxic Activity

The cytotoxicity against human hepatocellular carcinoma Hep G2 and human breast adenocarcinoma MCF-7 cell lines was tested by using sulforhodamine B (SRB) assay as previously described (Thao et al., 2014). Ellipcitine was used as the positive control. The test was done in triplicates to ensure accuracy.

Fermentation

A small-scale liquid fermentation was performed with YIM 61 medium (Qin et al., 2009) as the antibiotic producing medium (200 rpm, 28°C, 5 days). The scale up fermentation (20 L) was done using the New Brunswick BioFlo $^{(\!R\!)}$ /CelliGen $^{(\!R\!)}$ 115 Benchtop Fermentor & Bioreactor (28°C, 5 days). In both cases, seed culture for inoculation was prepared in ISP2 medium (200 rpm, 28°C, 4 days)

Extraction and Purification of the Active Compounds

The fermentation broth was centrifuged at 7000 rpm for 10 min. The supernatant fraction was then extracted thrice with ethyl acetate. The ethyl acetate layer was concentrated *in vacuo* to give ethyl acetate extract (SPA-E). The aqueous phase was filtered through a diaion HP20 column and eluted with water and methanol subsequently. The water eluent fraction was evaporated to give the extract designated as SPA-W1 while the methanol eluent was concentrated *in vacuo* to obtain a brown solid (SPA-W2).

Similarly, the mycelium cake obtained after centrifugation of the fermentation broth was processed to obtain a ethylacetate extract (SPB-E), a water eluent extract (EPB-W1) and a methanol eluent extract (SPB-W1). All these fractions were analyzed in Silica gel TLC sheet (Merck, Germany) using the dichloromethane-methanol (30:1, v/v) solvent system. Based on the similarity profiles in the TLC (Koup et al., 1978), SPA-E/SPB-E, SPA-W1/SPB-W1, and SPA-W2/SPB-W2 were pooled together and were designated as SP-E, SP-W1, and SP-W2, respectively. A schematic diagram representing the extraction protocol is shown in **Figure 1**. Each of these fractions was evaluated for antimicrobial and cytotoxic activities. The bioactive fractions were further purified using different solvent systems to obtain pure metabolite(s) as represented in **Figure 1B**.

Structure Elucidation of the Pure Active Compounds

The structure of the bioactive compound(s) was analyzed using mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy (Booth et al., 1976; Hamza et al., 2013). The results were compared with the available reference compounds and published literatures.

Determination of Antibacterial and Cytotoxic Effects of the Dragon's Blood Extracted from Medicinal Plant *D. cochinchinensis*

Dragon's blood in the xylem of the host plant was extracted as described by Wang et al. (2011). The dry weight of the extract was dissolved in 95% (v/v) alcohol and filtered through sterile filter membrane (0.22 μ m). The solution was then used for antibacterial and antitumor tests.

The MIC of Dragon's blood against MSSA ATCC 29213, MRSE ATCC 35984, *K. pneumoniae* ATCC 13883, and *E. coli* ATCC 25922 was determined by broth dilution method on 96-well plate as previously described (Andrews, 2001). The MIC against *F. graminearum* was determined according to Gopal et al. (2012). The SRB assay was used for determination the cytotoxic

effect of the Dragon's blood on human breast adenocarcinoma (MCF-7) and human hepatocellular carcinoma (Hep G2) cells (Thao et al., 2014).

Results

Characterization of Strain HUST012

Cells of the strain HUST012 was Gram-positive and aerobic. The strain formed extensively branched, non-fragmented substrate and aerial mycelia. Strain HUST012 formed straight or rectiflexibile spore chains with smooth surface. However, these spore chains generally contained less than 50 spores (Figure S1). The strain grew well on ISP 2, ISP 3, ISP 5, TSA, Czapek, and Nutrient agar media, with a gray color aerial mycelium. It produced green-yellow and yellow pigments on ISP2 and Czapek agar media respectively. Strain HUST012 was found to grow over a wide range of temperature (4–45°C) and pH (4.0–9.0) with optimal growth at 28°C and pH 6.0–7.0, and in the presence of upto 10% NaCl (w/v) with optimum at 1–3% NaCl.

HUST012 could utilize DL-alanine, L-arginine, L-asparagine, Glycine, DL-leucine, L-lysine, DL-serine, L-glutamic acid, DL-methionine, L-cystine, L-histidine as nitrogen resources; D-fructose, D-galactose, D-glucose, D-mannose, D-trehalose, D-sorbose, D-xylose, glycerol, and sodium acetate as carbon sources. The strain was positive for amylase and catalase activities, but was negative for nitrate reduction, H₂S production and gelatin reduction tests. Strain HUST012 showed highest 16S rRNA gene sequence similarities with *Streptomyces parvulus* (99.26%). Phylogenetic tree (**Figure 2**) based on neighbor-joining method also indicated its closest similarity to *Streptomyces parvulus*. The phenotypic and genomic data indicated that the strain HUST012 represented a strain of the genus *Streptomyces* for which the strain was referred to as *Streptomyces* sp. strain HUST012.


Antimicrobial and Cytotoxic Effects of Strain HUST012

The culture filtrate of strain HUST012 exhibited antibacterial activity against all tested Gram positive and Gram negative bacterial strains. The maximum activity was found against MRSE ATCC 35984 (inhibition zone of 35 mm diameter), followed by *A. hydrophila* ATCC 7966 (26 mm) and MSSA ATCC 29213 (25.80 mm). The detailed antimicrobial profiles are shown in **Table 1**.

The antifungal activity of *Streptomyces* sp. strain HUST012 was examined against three mycotoxin producing fungal strains. The fungal growth inhibition was observed in the order: *F. graminearum* (9.7 mm), *A. carbonarius* (7.7 mm), and *A. westerdijkiae* (1.8 mm).

Fermentation, Antimicrobial and Cytotoxic Effects of Bioactive Metabolites of Strain HUST012

Among the crude metabolites extracts of strain HUST012, the fraction SP-E showed the highest antibacterial and cytotoxic activities. This fraction was further purified by column chromatography with different gradient solvent systems as



depicted in **Figure 1**. Two bioactive metabolites, designated SPE-B11.8 and SPE-B5.4, were purified.

The MIC values of the metabolite SPE-B11.8 against the test bacterial organisms ranges between 15.63 and 62.5 $\mu g/ml$ while those for SPE-B5.4 ranges between 0.04 and 2.24 $\mu g/ml$ (Table 2).

Human hepatocellular carcinoma Hep G2 and human breast adenocarcinoma cell MCF-7 lines were used as model systems to examine the cytotoxic effect of *Streptomyces* sp. HUST012. The culture filtrate, crude metabolite extracts (SP-E, SP-W1, SP-W2) and the pure metabolites (SPE-B11.8 and SPE-B5.4) were examined for their cytotoxic effect on the two human cancer cell lines Hep G2 and MCF-7. The cytotoxic assay results showed that the culture filtrate of the strain HUST012 had significant inhibition toward Hep G2 and MCF-7 cells with IC_{50} -values of 4

and 3 μ g/ml, respectively. Among the crude metabolites extracts, SP-E showed the strongest cytotoxic effect with I C_{50} -values of 0.31 and 0.18 μ g/ml. The pure metabolites SPE-B11.8 showed cytotoxic effect at 41.63 and 29.54 μ g/ml I C_{50} -values against Hep G2 and MCF-7, respectively, while the metabolite SPE-B5.4 exhibited the same at 0.23 and 0.18 μ g/ml I C_{50} -values (**Table 3**).

Structure Elucidation of Bioactive Compounds

The structure of the compounds SPE-B11.8 and SPE-B5.4 were analyzed through the techniques of MS and NMR spectroscopy.

The compound **SPE-B11.8** was obtained as a colorless solid. Its HRESIMS spectrum showed a peak at m/z 315.1814 [M+H]⁺, corresponding to the molecular formula $C_{16}H_{27}O_6$. The 1D and 2D-NMR spectra of **SPE-B11.8** showed signals characteristic




TABLE 1 | Antimicrobial activities of the strain *Streptomyces* sp. HUST012 against bacterial and fungal strains.

Test strains	Inhibition zone (mm diameter)
GRAM POSITIVE BACTERIA	
Methicillin-resistant S. epidermidis ATCC 35984	35.00 ± 0.80
Methicillin-resistant S. aureus ATCC 25923	18.90 ± 1.67
Methicillin-susceptible S. aureus ATCC 29213	25.80 ± 1.47
Enterococcus faecalis ATCC 29212	20.00 ± 0.20
GRAM NEGATIVE BACTERIA	
Escherichia coli ATCC 25922	18.90 ± 1.00
Escherichia coli ATCC 11105	12.40 ± 0.73
Klebsiella pneumoniae ATCC 13883	19.80 ± 2.20
Aeromonas hydrophila ATCC 7966	26.00 ± 0.47
FUNGAL STRAINS	
Fusarium graminearum	9.70 ± 0.73
Aspergillus westerdijkiae	1.80 ± 0.47
Aspergillus carbonarius	7.70 ± 0.80

for a monounsaturated fatty acid with the double bond at δ_H 5.33/ δ_C 129.1–129.9, three carboxylic groups at δ_C 175.1, 178.1, and 181.1, and a cluster of methylenic protons at δ_C in the range of δ_C 24.6–35.1. The COSY and HMBC spectra led to the identification of the fragments of SPE-B11.8 structure (see Figure S2 for the complete NMR spectra). The position of the double

TABLE 2 | Antibacterial and cytotoxic effects of the compounds HPE-B11.8 and SPE-B5.4 in comparison with Dragon's blood extracted from medicinal plant *D. cochinchinensis* Lour.

Test organisms/cancer cell line	SPE-B11.8	SPE-B5.4	Dragon's blood extract
		MIC/IC ₅₀ (μg/ml)	
MRSE ATCC 35984	15.63 ± 1.18	0.04 ± 0.00	4.88 ± 0.05
MRSA ATCC 25923	62.5 ± 2.26	0.04 ± 0.00	4.88 ± 0.05
E. coli ATCC 25922	Inactive	2.24 ± 0.01	9.77 ± 0.23
K. pneumoniae ATCC 13883	62.5 ± 2.26	0.04 ± 0.00	4.88 ± 0.05
F. graminearum	Inactive	9.77 ± 0.23	19.53 ± 0.80
Hep G2	41.63 ± 0.61	0.23 ± 0.05	77.91 ± 0.22
MCF-7	29.54 ± 2.89	0.18 ± 0.05	70.00 ± 7.08

bond was also confirmed by the MS data with the fragment at m/z 128.08 and 187.08 corresponding to the breakdown at C-7 and C-8 liason. The configuration of the double bond was determined based the on the chemical shifts of vicinal carbon atoms. Both C-6 and C-9 appeared at δ_C 26.5 and 26.3 ppm indicating the Z configuration. Thus, compound SPE-B11.8 was newly elucidated to be (Z)-tridec-7-ene-1,2,13-tricarboxylic acid (**Figure 3**).

TABLE 3 | Cytotoxicity of test sample (IC₅₀ in μ g/ml).

Hep G2	MCF-7			
4.00 ± 0.10	3.00 ± 0.10			
0.31 ± 0.03	0.18 ± 0.02			
>100	>100			
>100	>100			
41.63 ± 0.61	29.54 ± 2.89			
0.23 ± 0.05	0.18 ± 0.05			
0.51 ± 0.08	0.47 ± 0.05			
	4.00 ± 0.10 0.31 ± 0.03 >100 >100 41.63 ± 0.61 0.23 ± 0.05			

HO
$$\begin{array}{c}
13 & 11 & 9 & 6 & 4 & 2 \\
10 & 8 & 7 & 3 & 1
\end{array}$$
HO
$$\begin{array}{c}
0 & OH \\
0 & OH
\\
OH
\end{array}$$
OH
$$\begin{array}{c}
OH \\
OH
\end{array}$$
OH
$$\begin{array}{c}
OH \\
OH
\end{array}$$
OH
$$\begin{array}{c}
OH \\
OH
\end{array}$$
OH
$$\begin{array}{c}
OH \\
OH
\end{array}$$
OH
$$\begin{array}{c}
OH \\
OH
\end{array}$$
OH
$$\begin{array}{c}
OH \\
OH
\end{array}$$

FIGURE 3 | Structure of the compound SPE-B11.8 (elucidated as (Z)-tridec-7-ene-1,2,13-tricarboxylic acid).

The compound **SPE-B5.4** was obtained as a red powder, soluble in methanol, ethyl acetate, ethanol, and DMSO, stable in aqueous solutions at 5–10°C. The HRESIMS spectrum revealed a peak at m/z 1255.6435 [M+H]⁺, corresponding to the formula $C_{62}H_{87}N_{12}O_{16}$ (Figure S3). The ¹H-NMR, ¹³C-NMR spectrum analysis data of the SPE-B5.4 compound is presented in Table S1. The spectral data was compared with the findings of Booth et al. (1976) and the compound SPEB-5.4 was identified as Actinomycin-D with molecular formula $C_{62}H_{86}N_{12}O_{16}$ (**Figure 4**).

Antibacterial and Cytotoxic Effects of the Dragon's Blood Extracted from Medicinal Plant *D. cochinchinensis*

The Dragon's blood extract was analyzed for its antibacterial and cytotoxic effects against MRSA, MRSE, *K. pneumoniae* and *E. coli*, and toward MCF-7 and Hep G2 cell lines. **Table 2** showed the MIC for the dragon's blood extracts in comparison with those of the crude metabolites extracts and the compounds SPE-B11.8 and SPE-B5.4.

Discussion

The antimicrobial resistance has been one of the most serious health threats. Infections from resistant bacteria are now too common, and some pathogens have even become resistant to multiple classes of antibiotics. The decline of effective antibiotics will undermine our ability to fight infectious diseases and manage the infectious complications common in vulnerable patients,

especially those undergoing chemotherapy for cancer, dialysis for renal failure, and organ transplantation. When first- and second-line antibiotic treatment options are limited by resistance and/or unavailability, healthcare providers are forced to use toxic antibiotics which are frequently more expensive but less effective. Even when alternative treatments are available, research has shown that patients with resistant infections are often much more likely to result in death, and that survivors require longer hospital stays, delayed recuperation, and long-term disability. Hence, there is an urgent need for search of novel drugs against such pathogens. It has been envisaged that endophytic environment is an extreme source to provide exciting new bioactive compounds.

In the present study, an attempt was tried to identify the bioactive potential of the endophytic actinobacterium *Streptomyces* sp. HUST012. The strain was found to exhibit antimicrobial activities against a set of pathogenic bacteria and fungi (**Table 1**). The presence of antifungal activities is also an indication of probable biocontrol mechanisms against mycotoxin producing fungal strains. Similar findings have been reported in similar studies of *Streptomyces* strains (Rahman et al., 2010; Usha et al., 2010; Naine et al., 2015).

The cytotoxic ability of this strain was significant as compared to that reported in previous studies on *S. parvulus* strain VITJS11 (Naine et al., 2015). The compounds SPE-B11.8 and SPE-B5.4 had IC_{50} -values of 41.63 and 0.23 µg/ml on Hep G2 cells as compared to 500 µg/ml by *S. parvulus* strain VITJS11. Other reports showed that migrastatin, a secondary metabolite from *Streptomyces* inhibited the Hep G2 cells at the concentration of 6 and 10 µM after 24 and 48 h of treatment (Rambabu et al., 2014). The high bioactive effect of *Streptomyces* sp. HUST012 can be explained by the fact that endophytic actinomycetes live in close association with their host plants and that it could become a real possibility for exchange of genes involved in natural products biosynthesis between endophytic actinomycetes and host plants via horizontal gene transfer, resulting in synthesis of plant-derived compounds by a microbial endophyte (Chandra et al., 2013).

An important finding of this current study was the isolation of the new compound HPE-B11.8 which was elucidated as (Z)tridec-7-ene-1,2,13-tricarboxylic acid, thereby underlying the importance of the source. The compound HPE-B11.8 possessed moderate antibacterial and anticancer activities against the test pathogenic microorganisms/cell lines. Another important finding was the isolation of Actinomycin D (compound SPE-B5.4). Actinomycin D was an antineoplastic antibiotic that inhibits cell proliferation. It finds wide range of applications, viz. as selective reagent in cell culture, studies in suppressing HIV-replication and programmed cell death of PC12 cells, and as an antibiotic in treatment of various malignant neoplasm including Wilm's tumor and the sarcomas. Actinomycin-D decreases Mcl-1 expression and acts synergistically with ABT-737 against small cell lung cancer cell lines (Aishan et al., 2010). According to the Internet bibliographic database-MEDLINE, actinomycins, especially Actinomycin-D, have been the subject of about 3300 research publications (Koba and Konopa, 2005). The isolation of Actinomycin-D is

not a new discovery but our present study proved that the medicinal plant *D. cochinchinensis* Lour. was a rich source of endophytic actinomycetes producing the potent antibiotic agents.

Dragon's blood has been well documented for its antimicrobial, antioxidant, anti-antitumor and cytotoxic properties. However, the host plant D. cochinchinensis Lour. has no secretory tissue to release this useful metabolite, and therefore Dragon's blood remains in xylem parenchyma cells of the stem. The growth of the plant is extremely slow and has low yield of dragon's blood. To harvest a few pieces of resinous wood, a tree with hundreds of years old is often destroyed. This work aimed to evaluate the antimicrobial and cytotoxic effects of the natural Dragon's blood extracted from medicinal plant *D*. cochinchinensis Lour. in comparison with that secreted by the endophytic Streptomyces sp. HUST012 associated with the host plant. Our results were significant in comparison to the findings of other research groups (Al-Fatimi et al., 2005; Wang et al., 2010, 2011). This could give us a suggestion for the promotion of the application of secondary bioactive metabolites from endophytic actinomycetes associated with the medicinal plant *D*. cochinchinensis Lour. instead of destroying valuable endangered trees

Acknowledgments

The authors would like to thank Dr. Samira Sarter (UMR QUALISUD, CIRAD, France) and Dr. Osama Abdalla Mohamed (Suez Canal University, Egypt) for their kind comments on this manuscript. This research was supported by Vietnam Ministry of Education and Training (B2014-01-79 project) and the Guangdong Province Higher Vocational Colleges & Schools Pearl River Scholar Funded Scheme (2014). The authors also thank to UMR QUALISUD, CIRAD, Montpellier, France for supporting the characterization of the HUST012 strain and determination of antifungal activity.

Supplementary Material

The Supplementary Material for this article can be found online at: http://journal.frontiersin.org/article/10.3389/fmicb. 2015.00574/abstract

References

Aishan, H., Baba, M., Iwasaki, N., Kuang, H., and Okuyama, T. (2010). The constituents of *Urtica cannabina* used in Uighur medicine. *Pharm. Biol.* 48, 577–583. doi: 10.3109/13880200903214215

Al-Fatimi, M., Friedrich, U., and Jenett-Siems, K. (2005). Cytotoxicity of plants used in traditional medicine in Yemen. *Fitoterapia* 76, 355–358. doi: 10.1016/j.fitote.2005.02.009 Anderson, A. S., and Wellington, E. M. (2001). The taxonomy of *Streptomyces* and related genera. *Int. J. Syst. Evol. Microbiol.* 51, 797–814. doi: 10.1099/00207713-51-3-797

Andrews, J. M. (2001). Determination of minimum inhibitory concentrations. J. Antimicrob. Chemother. 48, 5–16. doi: 10.1093/jac/48.suppl_1.5

Athalye, M., Goodfellow, M., Lacey, J., and White, R. P. (1985). Numerical classification of Actinomadura and Nocardiopsis. Int. J. Syst. Bact. 35, 86–98. doi: 10.1099/00207713-35-1-86

- Booth, H., Mauger, A. B., and Rzeszotarski, W. J. (1976). A ¹³C NMR study of actinomycin D and related model peptides. Org. Magn. Reson. 8, 219–223. doi: 10.1002/mrc.1270080413
- Chandra, S., Lata, H., and Varma, A. (2013). Biotechnology for Medicinal Plants-Micropropagation and Improvement. Berlin; Heidelberg: Springer-Verleg.
- Crnovcic, I., Vater, J., and Keller, U. (2013), Occurrence and biosynthesis of C-demethylactinomycins in actinomycin-producing Streptomyces chrysomallus and Streptomyces parvulus. J. Antibiot. 66, 211–218. doi: 10.1038/ja. 2012 120
- Fan, L. L., Tu, P. F., He, J. X., Chen, H. B., and Cai, S. Q. (2008). Microscopical study of original plant of Chinese drug "Dragon's Blood" *Dracaena cochinchinensis* and distribution and constituents detection of its resin. *Zhongguo Zhong Yao* Za Zhi 33, 1112–1117.
- Felsenstein, J. (1985). Confidence limits on phylogenies: an approach using the bootstrap. *Evolution* 39, 783–791. doi: 10.2307/2408678
- Goodfellow, M. (1971). Numerical taxonomy of some nocardioform bacteria. J. Gen. Microbiol. 69, 33–80. doi: 10.1099/00221287-69-1-33
- Gopal, R., Na, H., Seo, C. H., and Park, Y. (2012). Antifungal activity of (KW)n or (RW)n peptide against Fusarium solani and Fusarium oxysporum. Int. J. Mol. Sci. 13, 15042–15053. doi: 10.3390/ijms131115042
- Gupta, D., Bleakley, B., and Gupta, R. K. (2008). Dragon's blood: botany, chemistry and therapeutic uses. J. Ethnopharmacol. 115, 361–380. doi: 10.1016/j.jep.2007.10.018
- Hamza, A. A., Ali, H. A., Clark, B. R., Murphy, C. D., and Elobaid, E. A. (2013). Isolation and characterisation of actinomycin D producing *Streptomyces* spp. from Sudanese soil. *Afr. J. Biotechnol.* 12, 2624–2632. doi: 10.5897/AJB 12.1066
- Holder, I. A., and Boyce, S. T. (1994). Agar well diffusion assay testing of bacterial susceptibility to various antimicrobials in concentrations non-toxic for human cells in culture. *Burns* 20, 426–429. doi: 10.1016/0305-4179(94)90035-3
- Huffman, J., Gerber, R., and Du, L. (2010). Recent advancements in the biosynthetic mechanisms for polyketide-derived mycotoxins. *Biopolymers* 93, 764–776. doi: 10.1002/bip.21483
- Inbar, L., and Lapidot, A. (1988). Metabolic regulation in Streptomyces parvulus during actinomycin D synthesis, studied with 13C- and 15N-labeled precursors by 13C and 15N nuclear magnetic resonance spectroscopy and by gas chromatography-mass spectrometry. J. Bacteriol. 170, 4055–4064. doi:0021-9193/88/094055-10\$02.00/0
- Kawahara, T., Izumikawa, M., Otoguro, M., Yamamura, H., Hayakawa, M., Takagi, M., et al. (2012). JBIR-94 and JBIR-125, Antioxidative phenolic compounds from *Streptomyces* sp. R56-07. *J. Nat. Prod.* 75, 107–110. doi: 10.1021/np200734p
- Khamna, S., Yokota, A., and Lumyong, S. (2009). Actinomycetes isolated from medicinal plant rhizospheric soils: diversity and screening of antifungal compounds, indole-3-acetic acid and siderophore production. World J. Microbiol. Biotechnol. 25, 649–655. doi: 10.1007/s11274-008-9933-x
- Kim, O. S., Cho, Y. J., Lee, K., Yoon, S. H., Kim, M., Na, H., et al. (2012). Introducing EzTaxon-e: a prokaryotic 16S rRNA gene sequence database with phylotypes that represent uncultured species. *Int. J. Syst. Evol. Microbiol.* 62, 716–721. doi: 10.1099/ijs.0.038075-0
- Kimura, M. (1983). The Neutral Theory of Molecular Evolution. Cambridge: Cambridge University Press.
- Koba, M., and Konopa, J. (2005). Actinomycin D and its mechanisms of action. Postepy Hig. Med. Dosw. 59, 290–298.
- Koup, J. R., Brodsky, B., Lau, A., and Beam, T. R. Jr. (1978). High-performance liquid chromatographic assay of chloramphenicol in serum. *Antimicrob. Agents Chemother.* 14, 439–443.
- Li, J., Zhao, G. Z., Qin, S., Zhu, W. Y., Xu, L. H., and Li, W. J. (2009). Streptomyces sedi sp. nov., isolated from surface-sterilized roots of Sedum sp. Int. J. Syst. Evol. Microbiol. 59, 1492–1496. doi: 10.1099/ijs.0.007534-0
- Liu, Y., Tortora, G., Ryan, M. E., Lee, H. M., and Golub, L. M. (2002). Potato dextrose agar antifungal susceptibility testing for yeasts and molds: evaluation of phosphate effect on antifungal activity of CMT-3. *Antimicrob. Agents Chemother.* 46, 1455–1461. doi: 10.1128/AAC.46.5.1455-1461.2002
- Mechri, B., Manga, A. G. B., Tekaya, M., Attia, F., Cheheb, H., Meriem, F. B., et al. (2014). Changes in microbial communities and carbohydrate profiles induced by the *mycorrhizal* fungus (*Glomus intraradices*) in rhizosphere

- of olive trees (Olea europaea L.). Appl. Soil Ecol. 75, 124–133. doi: 10.1016/j.apsoil.2013.11.001
- Naine, S. J., Devi, C. S., Mohanasrinivasan, V., and Vaishnavi, B. (2015).
 Antimicrobial, antioxidant and cytotoxic activity of marine Streptomyces parvulus VITJS11 crude extract. Braz. Arch. Biol. Technol. 58, 198–207. doi: 10.1509/S1516-8913201400173
- Olano, C., Moss, S. J., Braña, A. F., Sheridan, R. M., Math, V., Weston, A. J., et al. (2004). Biosynthesis of the angiogenesis inhibitor borrelidin by *Streptomyces parvulus* Tü4055: insights into nitrile formation. *Mol. Microbiol.* 52, 1745–1756. doi: 10.1111/j.1365-2958.2004.04090.x
- Pridham, T. G., and Gottlieb, D. (1948). The utilization of carbon compounds by some *Actinomycetales* as an aid for species determination. *J. Bacteriol.* 56, 107–114.
- Qin, S., Li, J., Chen, H. H., Zhao, G. Z., Zhu, W. Y., Jiang, C. L., et al. (2009). Isolation, diversity, and antimicrobial activity of rare actinobacteria from medicinal plants of tropical rain forests in Xishuangbanna, China. Appl. Environ. Microbiol. 75, 6176–6186. doi: 10.1128/AEM. 01034-09
- Qin, S., Xing, K., Jiang, J. H., Xu, L. H., and Li, W. J. (2011). Biodiversity, bioactive natural products and biotechnological potential of plant-associated endophytic actinobacteria. *Appl. Microbiol. Biotechnol.* 89, 457–473. doi: 10.1007/s00253-010-2923-6
- Rahman, M. A., Islam, M. Z., Khondkar, P., and Islam, M. A. U. (2010). Characterization and antimicrobial activities of a polypeptide antibiotic isolated from a new strain of *Streptomyces parvulus*. *Bangladesh Pharm. J.* 13, 14–17.
- Rambabu, V., Suba, S., Manikandan, P., and Vijayakumar, S. (2014). Cytotoxic and apoptotic nature of migrastatin, a secondary metabolite from *Streptomyces* evaluated on HEP G2 cell line. *Int. J. Pharm. Pharm. Sci.* 6, 333–338.
- Rehm, S., Han, S., Hassani, I., Sokocevic, A., Jonker, H. R., Engels, J. W., et al. (2009). The high resolution NMR structure of parvulustat (Z-2685) from Streptomyces parvulus FH-1641: comparison with tendamistat from Streptomyces tendae 4158. Chembiochem 10, 119–127. doi:10.1002/cbic.200800547
- Saitou, N., and Nei, M. (1987). The neighbour-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4, 406–425.
- Shirling, E. B., and Gottlieb, D. (1966). Methods for characterization of Streptomyces species. Int. J. Syst. Bacteriol. 16, 313–340. doi: 10.1099/00207713-16-3-313
- Subramani, R., and Aalbersberg, W. (2012). Marine actinomycetes: an ongoing source of novel bioactive metabolites. *Microbiol. Res.* 167, 571–580. doi: 10.1016/j.micres.2012.06.005
- Tamura, K., Stecher, G., Peterson, D., Filipski, A., and Kumar, S. (2013), MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol. Biol. Evol. 30, 2725–2729. doi: 10.1093/molbev/mst197
- Thao, D. T., Phuong, D. T., Hanh, T. T. H., Thao, N. P., Cuong, N. X., Nam, N. H., et al. (2014). Two new neoclerodane diterpenoids from Scutellaria barbata D. Don growing in Vietnam. J. Asian Nat. Prod. Res. 16, 364–369. doi: 10.1080/10286020.2014.882912
- Thompson, J. D., Gibson, T. J., Plewniak, F., Jeanmougin, F., and Higgins, D. G. (1997). The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. *Nucleic Acids Res.* 25, 4876–4882. doi: 10.1093/nar/25.24.4876
- Tindall, B. J., Sikorski, J., Smibert, R. A., and Krieg, N. R. (2007). "Phenotypic characterization and the principles of comparative systematics," in *Methods for General and Molecular Microbiology, 3rd Edn.*, eds C. A. Reddy, T. J. Beveridge, J. A. Breznak, G. A. Marzluf, T. M. Schmidt, and L. R. Snyder (Washington, DC: ASM Press), 330–393. doi: 10.1128/9781555817 497.ch15
- Usha, R., Ananthaselvi, P., Venil, C. K., and Palaniswamy, M. (2010). Antimicrobial and antiangiogenesis activity of *Streptomyces parvulus* KUAP106 from Mangrove Soil. Eur. J. Biol. Sci. 2, 77–83.
- Wang, X. H., Zhang, C., Yang, L. L., and Gomes-Laranjo, J. (2011). Production of dragon's blood in *Dracaena cochinchinensis* plants by inoculation of *Fusarium proliferatum*. *Plant Sci.* 180, 292–299. doi: 10.1016/j.plantsci.2010. 09.007

- Wang, X. H., Zhang, C. H., Wang, Y., and Gomes-Laranjo, J. (2010). Screen of micro-organisms for inducing the production of dragon's blood by leaf of *Dracaena cochinchinensis*. Lett. Appl. Microbiol. 51, 504–510. doi: 10.1111/j.1472-765X.2010.02921.x
- Xu, P., Li, W. J., Tang, S. K., Zhang, Y. Q., Chen, G. Z., Chen, H. H., et al. (2005). Naxibacter alkalitolerans gen. nov., sp. nov., a novel member of the family 'Oxalobacteraceae' isolated from China. Int. J. Syst. Evol. Microbiol. 55, 1149–1153. doi: 10.1099/ijs.0.63407-0
- Zhang, Y. Q., Liu, H. Y., Chen, J., Yuan, L. J., Sun, W., Zhang, L. X., et al. (2010). Diversity of culturable actinobacteria from Qinghai-Tibet plateau, China. Antonie Van Leeuwenhoek 98, 213–223. doi: 10.1007/s10482-010-9434-4

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2015 Khieu, Liu, Nimaichand, Quach, Chu-Ky, Phi, Vu, Nguyen, Xiong, Prabhu and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.